Hormone therapies in prostate cancer, less but better

Poster Session 67

  • Location:
    Room Stockholm (Hall B2, level 0)
  • Chairs:
     S. Bracarda, Perugia (IT)
     F. Calais Da Silva Junior, Lisbon (PT)
     J. Morote Robles, Barcelona (ES)
  • Aims and objectives of this session

    Hormone therapy remains the mainstay systemic treatment of advanced prostate cancer. Despite almost 60 years of use the optimal timing and modalities remain to be determined. This session will focus on recent updates.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
* 843
Phase III study of intermittent monotherapy versus continuous combined androgen deprivation

By: Calais Da Silva Junior F.1, Calais Da Silva Senior F.E.2, Gonçalves F.3, Kliment J.4, Santos A.5, Spyros P.6, Queimadelos A.7, Robertson C.8

Institutes: 1CHLC – Hospital De São José, Dept. of Urology, Lisbon, Portugal, 2CHLC – H.S.José, Dept. of Urology, Lisbon, Portugal, 3CUIMED A Saint Michal Hospital, Dept. of Urology, Bratislava, Slovakia, 4Jessenius School of Medicine, Dept. of Urology, Martin, Slovakia, 5Hospital De Braga, Dept. of Urology, Braga, Portugal, 6Amalia Fleming Hospital, Dept. of Urology, Athens, Greece, 7Policlinica La Rosaleda, Dept. of Urology, Santiago Compostela, Spain, 8University of Stracthclyde, Dept. of Statistics, Glasgow, United Kingdom

* 844
Survival outcomes in octogenarian and nonagenarian patients treated with first-line androgen deprivation therapy for localized prostate cancer

By: Dell’Oglio P.1, Bishr M.1, Boehm K.2, Trudeau V.1, Larcher A.3, Tian Z.4, Saad F.5, Capitanio U.3, Briganti A.3, Graefen M.2, Montorsi F.3, Karakiewicz P.1

Institutes: 1Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Dept. of Urology, Montreal, Canada, 2Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 3Irccs Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy, 4McGill University, Dept. of Epidemiology, Biostatistics and Occupational Health, Montreal, Canada, 5University of Montreal Health Center, Dept. of Urology, Montreal, Canada

Timing of the development of metastasis and initiation of treatment are important prognostic factors in prostate cancer

By: Frees S., Akamatsu S., Lynch K., Chavez-Munoz C., Black P., Gleave M., Goldenberg L., Chi K., So A.

Institutes: Vancouver Prostate Centre, Dept. of Urological Sciences, Vancouver, Canada

Peri-prostatic fat volume predicts castration resistance in advanced prostate cancer

By: Hendry J.1, Patel A.2, Leung H.1, Salji M.1

Institutes: 1Beatson Institute For Cancer Research, Dept. of Urology, Glasgow, United Kingdom, 2Queen Elizabeth University Hospital, Dept. of Radiology, Glasgow, United Kingdom

Impact of free testosterone levels on the outcome of androgen deprivation therapy in metastatic prostate cancer

By: Mandhani A., Agnihotri S., Singh R.

Institutes: Sanjay Gandhi Post Graduate Institute of Medical Sciences, Dept. of Urology, Lucknow, India

Degarelix is well tolerated and effective for the treatment of prostate cancer: Results from a phase III study in China

By: Xie L.1, Bosnyák Z.2, Sun Y.3, Malmberg A.2, Neijber A.2, Fen W.X.4

Institutes: 1The First Affiliated Hospital of College of Medicine, Zhejiang University School of Medicine, Dept. of Urology, Zhejiang Province, China, 2Ferring Pharmaceuticals A/S, Dept. of Global Clinical Research and Development, Copenhagen, Denmark, 3Changhai Hospital The First Affiliated Hospital of The Second Military Medical University (SMMU), Dept. of Urology, Shanghai, China, 4Peking University People’s Hospital, Dept. of Urology, Beijing, China

Nomograms to estimate castration resistance and cancer specific survival in patients with advanced prostate cancer - GESCAP Study

By: Gómez-Veiga F.1, Rodriguez-Antolín A.2, Miñana B.3, Cozar J.M.4, Pedrosa E.5

Institutes: 1Hospital Universitario De Salamanca IBSAL, Dept. of Urology, Salamanca, Spain, 2Hospital Universitario 12 De Octubre, Dept. of Urology, Madrid, Spain, 3Hospital Morales Meseguer, Dept. of Urology, Murcia, Spain, 4Hospital Universitario Virgen De Las Nieves, Dept. of Urology, Granada, Spain, 5Astellas Pharma S.A., Medical Department, Madrid, Spain

Toremifene plus androgen deprivation therapy (TOPADT) significantly improved biochemical recurrence in bone metastatic prostate cancer: A randomized controlled phase IIA trial

By: Fujimura T.1, Takahashi S.2, Kume H.1, Urano T.3, Takayama K.3, Yamada Y.1, Suzuki M.1, Fukuhara H.1, Nakagawa T.1, Inoue S.4, Homma Y.1

Institutes: 1The University of Tokyo, Dept. of Urology, Tokyo, Japan, 2The Nihon University, Dept. of Urology, Tokyo, Japan, 3The University of Tokyo, Dept. of Geriatric Medicine, Tokyo, Japan, 4The University of Tokyo, Dept. of Anti-Aging Medicine, Tokyo, Japan

Clinocopathological features of patients progressed into castration-resistant prostate cancer after radical prostatectomy

By: Yoo S., Han J.H., Shin J., Lee C., You D., Jeong I.G., Hong J., Ahn H., Kim C.S.

Institutes: Asan Medical Center, Dept. of Urology, Seoul, South Korea

The impact of androgen deprivation therapy on body composition and hepatic fat content among men with prostate cancer

By: Ostergren P.B.1, Chabanova E.2, Fode M.1, Bennedbæk F.N.3, Faber J.3, Sonksen J.1, Kistorp C.3

Institutes: 1Herlev and Gentofte University Hospital, Faculty of Health and Medical Sciences, Copenhagen Universi, Dept. of Urology, Herlev, Denmark, 2Herlev and Gentofte University Hospital, Faculty of Health and Medical Sciences, Copenhagen Universi, Dept. of Radiology, Herlev, Denmark, 3Herlev and Gentofte University Hospital, Faculty of Health and Medical Sciences, Copenhagen Universi, Dept. of Endocrinology, Herlev, Denmark

Prevalence of hand joint symptoms of androgen deprivation therapy in Japanese prostate cancer patients

By: Inoue S., Kitano H., Hieda K., Shinmei S., Shoji K., Hayashi T., Teishima J., Matsubara A.

Institutes: Hiroshima University, Dept. of Urology, Hiroshima, Japan

Fracture risk assessment of men treated with androgen deprivation therapy for prostate cancer

By: Turo R.1, Calinciuc A.1, Horsu S.1, Stephens L.1, Nikomanis P.1, Smolski M.2, Gulur D.1, Das S.1, Awsare N.1, Pettersson B.1, Sinclair A.3, Oakley N.3, Adeyoju A.3, Bromage S.3, Brown S.3, Brough R.3, Collins G.3, Cross W.4

Institutes: 1Countess of Chester Hospital, Dept. of Urology, Chester, United Kingdom, 2Royal Preston Hospital, Dept. of Urology, Preston, United Kingdom, 3Stepping Hill Hospital, Dept. of Urology, Stockport, United Kingdom, 4St James’s University Hospital, Dept. of Urology, Leeds, United Kingdom

Summary and context
 F. Calais Da Silva Junior, Lisbon (PT)